KSKeerti Sitani

Keerti Sitani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Keerti Sitani has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Rahul Vithalrao Parghane

    Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe, Jerbai Wadia Road, Parel, Mumbai, India

    2 shared publications
  • Sandhya Mangalore

    Department of Neuroimaging and Interventional Radiology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India

    2 shared publications
  • Sandip Basu

    Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, India

    2 shared publications
  • Sanjay Talole

    Department of Head and Neck Surgery, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India

    2 shared publications
  • Dinesh Kumar S.

    National Institute of Mental Health and Neurosciences, India

    1 shared publication
  • M. Sandhya

    National Institute of Mental Health and Neurosciences, India

    1 shared publication

Latest Publications

  • Open Access

    Role of 6-Fluoro-18F-l-3,4-DOPA MR-PET in Clinical Workup in Movement Disorders Cases: An Exploratory Study in a Tertiary Care Neuropsychiatric Setup

    by Keerti Sitani, Sandhya Mangalore, Manoj Kumar Verma, Pardeep Kumar, Pawan Bairwa Btech, Venkatesh Murthy Konappa Agrahara Shama

    Introduction: 6-Fluoro-18F-l-3,4-dihydroxyphenylalanine (18F-DOPA) is primarily used to differentiate nondopamine deficient symptomatic subjects from Parkinsonian disorders and various etiologies from one another, which otherwise can be challenging. The current study aimed to determine (18F)-DOPA positron emission tomography (PET) patterns in Idiopathic Parkinson’s disease (IPD), nondopamine deficient symptomatic (NDDS) and other movement disorders. Materials and Methods: Sixty patients referred from neuropsychiatric outpatient department were retrospectively analyzed who underwent (18F)-DOPA magnetic resonance (MR)-PET scans. Out of 60 subjects, 36 were diagnosed with IPD, 5 were cases of other movement disorders, and 19 were normal on PET imaging (NDDS). To evaluate and quantify the tracer uptake from the PET scans, a region of interest (ROI) was drawn on the least radiotracer uptake region, and subsequently, on bilateral occipital cortex, caudate (head, body, tail), putamen (anterior, posterior), periaqueductal gray matter and red nucleus using structural MR images (MRI) for better delineation of anatomical regions. Tracer uptake ratios from each selected region were generated as SUV max of ROI/occipital. The statistical analysis was performed using SPSS 29.0 version. Results: The posterior putamen showed a significant difference between IPD and other patients with an SUV cutoff of 1.69 and 100% specificity and 99.2% accuracy for normal controls. Whereas, we observed an SUV cutoff of 1.75 and an accuracy and specificity of 100% in patients with other movement disorders. The absolute values from the caudate nucleus were demonstrating a statistical significance between other movement disorders compared to normal controls with a cutoff of 1.69 and an accuracy of 81.2%. The ratio of posterior putamen/occipital ratio was significant between IPD and normal controls, with a cutoff of 3.89 and an accuracy of 95.6%. Right caudate to occipital ratio (RCOR) was significant for differentiating between other movement disorders and normal controls with a cutoff of 3.01 and an accuracy of 95.6%. One novel finding was that occipital lobe uptake was significantly reduced in patients with IPD compared to other movement disorders. Conclusion: The findings from the current study demonstrated that hybrid imaging using 18F-DOPA PET/MRI could efficiently differentiate between various causes of Parkinson’s disease with diagnostic accuracy and necessary cut-offs.

  • Open Access

    A Rare Case of Asymmetric Progressive Supra Nuclear Palsy Diagnosed In vivo with Magnetic Resonance/Positron Emission Tomography

    by Keerti Sitani, Sandhya Mangalore, Nitish Kamble, Pramod Kumar Pal, Vikram Venkayappa Holla

    PSP and CBD are usually multi system sporadic disorders characterized by tau inclusions in neurons and glia. The clinical and neuroimaging features are different .However in some cases overlapping of features are noted. Here we present a case of a 65 years old female patient, presenting a 3 years history of insidious onset of asymmetric right upper and lower limb dystonia, followed by slowness, falls and injuries to the back, Parkinsonism, urinary incontinence and cognitive dysfunction and upward gaze palsy. MRI findings were suggestive of moderate cerebral and cerebellar atrophy with prominent ventricular system, reduced antero-posterior midline midbrain diameter, at the level of superior colliculus on axial imaging (morning glory sign was positive) on the left side. PET showed asymmetric hypo metabolism noted in the left superior and middle frontal gyrus, superior temporal and mid temporal gyrus in addition to striatum and thalamus, as well as midbrain, pons and right cerebellar hemisphere. Overall MR/PET was suggestive of unilateral PSP (left) and it corroborated with clinical history of unilateral dystonia and supranuclear gaze palsy. Based on MRI the differential considered was also CBD, but PET showed metabolic activity in the motor cortex. Additionally based on the hummingbird sign and morning glory sign a rare diagnosis of unilateral PSP could be made which also corroborated with the clinical picture.The case report emphasizes the utility of PETMRI simultaneously in situations like these to pick atypical variants or cases with overlapping pathology to reach a diagnosis with in vivo imaging methods.

  • Open Access

    Comparative Analysis and Experience of Various Amino Acid PET Tracers in a Tertiary Neuro-oncology Center—Indications, Patterns, Advantages, and Pitfalls

    by Keerti Sitani, M. Sandhya, Dinesh Kumar S.

    Keerti.sitani@gmail.com Introduction: Molecular imaging has been increasingly used in supplementing MRI imaging, for there clinical management, hence PET provides understanding beyond MRI into the biology and treatment response of gliomas which may be used for noninvasive grading, differential diagnosis, delineation of tumor extent, surgical and radiotherapy treatment planning, posttreatment surveillance, and prognostication. Methods: A total of 169 glioma patients were retrospectively analyzed. The main radiotracers used were: 13N ammonia, 18F choline, 11C methionine, 18F DOPA, and 18F FET. Each scan was assessed for recurrence/radiation necrosis by a trained nuclear medicine physician and a radiologist. We have correlated and standardized our findings with advanced MRI techniques and FDG pet which is standard of care in a neuro-oncology case. Results: 13N ammonia uptake by passive diffusion, physiological distribution involved the gray matter, basal ganglia, venous sinuses, pituitary gland, and lacrimal glands. Three cases showed intense uptake in the recurrence concordant with MRI. Major pitfall was the intense background uptake, pituitary uptake, and a short half-life. 18F Choline, 11C methionine uptake by LAT1, physiological distribution cerebral cortex, vascular structures, basal ganglia, cerebellum, scalp and salivary glands (parotid gland), pituitary gland, pineal body, choroid plexus and bone marrow (temporo-mandibular joint and vertebral bodies). A total of 110 cases showed increased uptake in the lesion. Pitfall was it could not be used for pituitary and has short half-life. 18F FET (56 cases) is currently in use; uptake by LAT 1, physiological distribution seen in vascular structures, basal ganglia, cerebellum, scalp, sinus mucosa, temporalis and pterygoid muscles, eyelids, optic nerve and optic chiasma, salivary glands, pineal body, choroid plexus and clivus bone marrow, extraocular muscles of the eye. 53/56 cases showed MRI concordant recurrence, and 3/56 showed discordant uptake. Advantageous as no pituitary uptake and longer half-life. Conclusion: The present analysis shows a trail of radiotracers that were used for neuro-oncology and left for specific reasons as mentioned above, hence emphasizes the evolution of radiotracers in oncology over time. Article published online: 25 May 2023 © 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • The efficacy, toxicity and survival of salvage retreatment PRRT with 177Lu-DOTATATE in patients with progressive NET following initial course of PRRT

    by Keerti Sitani, Rahul Parghane, Sanjay Talole, Sandip Basu

    Objective: To evaluate the efficacy, toxicity and survival of salvage peptide receptor radionuclide therapy (PRRT) with indigenous, direct-route 177Lu-labelled-DOTATATE in metastatic Nueroendocrine tumor (NET) patients who showed an objective response or disease stabilization following initial course of 177Lu-DOTATATE PRRT cycles and eventually developed progressive disease after a time-interval of more than 1 year; the variables influencing survival and response of salvage PRRT were also examined. Methods: A total of 26 progressive metastatic NET patients who received salvage PRRT with indigenous 177Lu-DOTATATE, were evaluated. Response was assessed under three broad categories as clinical symptomatic, biochemical and imaging (both molecular and morphological imaging). The Kaplan–Meier product-limit method was used to calculate progression-free survival (PFS) and overall survival (OS). Toxicity of salvage PRRT was evaluated by NCI-CTCAE v. 5.0 criteria (included complete blood counts, renal and liver function tests). Association between various variables and response and survival were analyzed using the χ2 test. Results: Out of the 26 patients, the complete follow-up data were not available for four patients, where only survival information was available. Thus, a total of 22 patients (median age: 55 years, range: 38–68 years, 12 men and 10 women) were included and analyzed retrospectively in study. The cumulative dose of initial course of PRRT (I-PRRT) with indigenous 177Lu-DOTATATE ranged from 800 mCi (29.6 GBq) to 1231 mCi (45.54 GBq) per patient {mean administered cumulative dose of 964 mCi (35.66 GBq) per patient}, and the salvage PRRT with indigenous 177Lu-DOTATATE comprised of a mean dose of 170 mCi (6.29GBq) per patient. The disease control rate of 68.1%, 77.3%, 63.6% and 63.6% were observed after salvage PRRT on clinical symptomatic, biochemical, molecular and morphological imaging response respectively. The median PFS after salvage PRRT was 17 months. The median OS was not attained after I-PRRT (OS-i) and salvage PRRT (OS-s). Estimated OS-i rate was 68% at 108 months and OS-s rate was 82% at 18 months. None of the patients developed Grade 3/4 hematotoxicity, nephrotoxicity and hepatotoxicity or AML/MDS after I-PRRT and salvage PRRT at median follow-up of 72 months and 12 months respectively. The highest level of toxicity was Grade 2 [seen as reversible anemia, thrombocytopenia and nephrotoxicity in 3 (13.5%), 1 (4.5%) and 2 patients (9%) respectively]. The significant p-value was not observed for any variable association. Conclusion: With limited therapeutic options available for progressive NET after I-PRRT and in the absence of high-grade toxicity after 177Lu-DOTATATE salvage PRRT, retreatment with PRRT may be considered as a relatively safe therapeutic option for these patients. Advances in knowledge: This study examined salvage retreatment PRRT with indigenous “direct-route” 177Lu-DOTATATE and registered its safety and survival benefits, indicating this could be an effective therapeutic option in this clinical setting.


  • Long-term outcome of indigenous 177Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting

    by Keerti Sitani, Rahul V Parghane, Sanjay Talole, Sandip Basu

    Objectives: Assessment of long-term outcome and toxicity of indigenous 177Lu-DOTATATE PRRT in patients of metastatic/advanced NETs in a large tertiary-care PRRT setting. Methods: A total of 468 metastatic/advanced NET patients (wide range of primary sites including CUP-NETs), who underwent at least two cycles of 177Lu-DOTATATE PRRT with available follow-up information, were included and analysed retrospectively in this study. In-house labelling of DOTATATE with 177Lu (direct route produced) was carried out in the hospital radiopharmacy and treatment administered in cycles (dose: 5.55 to 7.4 GBq per patient), at 10–12 weeks interval. The assessment of long-term outcome was undertaken under three broad headings: (a) Therapeutic response, (b) Survival outcome and (c) Toxicity assessment. The median point estimate with 95% CI for progression free survival (PFS) and overall survival (OS) were calculated by Kaplan–Meier method. Prognostic covariates for association with PFS and OS was investigated by Cox proportional hazards model (univariate and multivariate Hazard Ratios) and with disease control rate (DCR) by Chi-square test, with significant P value defined as <0.05. Results: Long-term outcome (follow-up ranging from 4 to 97.6 months; median period:46 months following first 177Lu-DOTATATE PRRT) results showed, (i) on symptomatic response evaluation scale, complete response (CR) in 214 patients (45.7%), partial response (PR) in 108 (23.1%), stable disease (SD) in 118 (25.2%), progressive disease (PD) in 28 (6%). (ii) Biochemical response evaluation showed CR in 52 (12%), PR in 172 (40%), SD in 161 (38%), and PD in 42 patients (10%). (iii) Molecular imaging response (by PERCIST criteria) showed CR in 29 (6%), PR in 116 (25%), SD in 267 (57%) and PD in 56 (12%) patients. (iv) On RECIST 1.1 criteria, CR was observed in 14 patients (3%), PR in 126 patients (27%), SD in 282 patients (60%) and PD in 46 patients (10%). The median PFS and OS were not reached at a median follow-up of 46 months. Observed PFS and OS at 7 years were 71.1% 95% CI (62.4–79.7%) and 79.4% 95% CI (71.4–86.9%) respectively. PFS was dependent on previous history of chemotherapy, baseline 68Ga-DOTATATE and 18F-FDG uptake, site of primary tumour, total cumulative dose and number of PRRT cycles on univariate analysis, whereas multivariate analysis showed significant association for previous history of chemotherapy, baseline 68Ga-DOTATATE and 18F-FDG uptake and number of PRRT cycles. The OS was dependent on baseline 68Ga-DOTATATE uptake, site of primary tumour, presence of bony metastatic disease, total cumulative dose and number of PRRT cycles on univariate analysis, whereas multivariate analysis showed significant association for bony metastatic disease and number of PRRT cycles. Transient haematological toxicity of Grade 1, Grade 2, and Grade 3 was found in 8 (1.7%), 1 (0.2%) and one patient (0.2%), respectively. Nephrotoxicity of Grade 1, Grade 2, Grade 3, and Grade 4 were seen in 16 (3.5%), 3 (0.6%), 2 (0.4%) and one patient (0.2%), respectively. On a separate sub-analysis of 322 NET patients with progressive disease at the initiation point of PRRT, overall response rates (CR + PR + SD) were 93.5%, 88.5%, 89.1 and 87.9% on symptomatic, biochemical, RECIST 1.1 and PERCIST criteria and PFS and OS at 7 years 68.3% and 79.2%, respectively. Conclusions: The present results demonstrate that 177Lu-DOTATATE PRRT improved symptoms and biochemical markers substantially in most of the NET patients, with disease stabilisation on both anatomical and molecular imaging in majority and response in a sizeable fraction. Additionally, the therapeutic protocol with lesser dose per cycle (mean 5.92 GBq/cycle) and prolonged duration (over 5 cycles and 1.5 years) in a metastatic NET setting proved equally efficacious (with superior PFS and OS rates) and relatively better tolerated with minimal toxicity. Advances in knowledge: The present work critically examines the long-term results, survival outcome and toxicity profile of the indigenous 177Lu-DOTATATE (produced through direct neutron activation of enriched 176Lu) in metastatic progressive NETs across a wide range of primary sites and malignancies. Such long-term outcome data establishes the favourable impact of PRRT in a wide patient base and also the therapeutic efficacy of the product.